Dana-Farber to Provide Hematology/Oncology Care at Holy Family Hospital in Methuen Beginning June 1

Extends Oncology Partnership between Steward and Dana-Farber

On June 1st, Dana-Farber Community Cancer Care (DFCCC) will open at Holy Family Hospital’s Methuen campus, which has been renovated for their arrival. DFCCC is transferring its current practice, located on Holy Family Hospital’s Haverhill campus, to this new location. This new site is an extension of Steward and Dana-Farber’s oncology affiliation, which currently includes Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center in Brighton, MA, and all DFCCC physician practices.

“This is a significant milestone for our local community and we are very pleased to welcome the Dana-Farber Community Cancer Care team to our campus,” said Joseph Roach, president of Holy Family Hospital in Methuen and Haverhill. “Our patients and their families who are facing this disease will have access to Dana-Farber’s highly regarded hematology/oncology care right here, at Holy Family Hospital, where many patients currently get primary care and other specialty care.”

 "We are very pleased to offer this option for patients with cancer in the Merrimack Valley,” said Dr. Andrew Norden, chief medical officer of DFCCC. “At the new site, Steward patients will be able to get sophisticated cancer care in a convenient, community setting closer to home.”

 Holy Family Hospital’s Medical Oncologists Drs. Laura Caprario and Ankur Mehta will be joining the DFCCC team and will continue to provide hematology/oncology care to patients, full-time, along with Dr. Catherine Iasiello from DFCCC. Staff in the newly renovated unit at Holy Family Methuen will follow the same policies, procedures, and quality standards used throughout DFCCC’s network of care, and patients will have easy access to advanced care and resources, such as clinical trials, at Dana-Farber’s headquarters in Boston and locations throughout New England, if needed. Steward patients, who had temporarily transferred their care to DFCCC Haverhill while renovations at Holy Family were ongoing, will transfer back to the DFCCC unit at Holy Family Methuen when the unit opens.

About Holy Family Hospital
Holy Family Hospital (www.holyfamilyhospital.org) is a 383-bed acute-care hospital with two campuses, Holy Family Hospital in Methuen and Holy Family Hospital at Merrimack Valley in Haverhill. Both locations provide comprehensive inpatient, outpatient and 24/7 emergency services to the greater Merrimack Valley, southern New Hampshire and the New Hampshire seacoast. Holy Family Hospital’s Methuen and Haverhill campuses are proud recipients of the Gold Seal of Approval from The Joint Commission. Both campuses have also earned “A” Hospital Safety Scores from The Leapfrog Group for their performance on national standards of safety, quality and efficiency. Holy Family Hospital is part of the Steward Health Care Systems LLC, the largest integrated community care organization in New England, which combines over 3,000 physicians, 10 acute care hospitals, managed care, insurance programs, home care, an imaging operation, and a number of other post acute services, to provide the most cost effective and highest quality of integrated patient care.

 About Dana-Farber Community Cancer Care
Dana-Farber Community Cancer Care (www.dana-farber.org/communitycare) is a part of Dana-Farber Cancer institute and operates 7 physician practices in Massachusetts. With practices in Dorchester, Lawrence, Methuen, Milton, Quincy Stoneham, and Weymouth, DFCCC provides patients with local access to Dana-Farber care. Dana-Farber Community Cancer Care physician practices are QOPI® Certified Practices, an independent acknowledgement that these practices meet specific quality and safety standards.



John Noble
[email protected]                                                                                                                                                                              
(617) 632-4090

Anna Frankenfield
[email protected]
978-687-0156, ext. 2659

Top news

Back to all news

Top news

Back to all news